BioPorto Asset Resilience Ratio
BioPorto asset resilience ratio. BioPorto (BIOPOR) has an Asset Resilience Ratio of 55.77% as of March 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BIOPOR defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of BioPorto (1999–1999)
Asset resilience ratio of BioPorto from 1999 to 1999. This chart shows how BioPorto's Asset Resilience Ratio has changed over time. Read BioPorto balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down BioPorto's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BIOPOR total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 0% |
| Short-term Investments | Dkr91.05 Million | 55.77% |
| Total Liquid Assets | Dkr91.05 Million | 55.77% |
Asset Resilience Insights
- Very High Liquidity: BioPorto maintains exceptional liquid asset reserves at 55.77% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
BioPorto Industry Peers by Asset Resilience Ratio
Compare BioPorto's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Diagnósticos da América S.A
SA:DASA3 |
Diagnostics & Research | 10.42% |
|
SMO ClinPlus Co. Ltd.
SHE:301257 |
Diagnostics & Research | 15.78% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
BioPorto Asset Resilience Ratio by Year (1999–1999)
BioPorto asset resilience ratio by year from 1999 to 1999. The table below shows the annual Asset Resilience Ratio data for BioPorto.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 1999-12-31 | 0.51% | Dkr69.00K ≈ $10.80K |
Dkr13.48 Million ≈ $2.11 Million |
-- |
About BioPorto
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination o… Read more